EntSun News

Popular on EntSun


Similar on EntSun

New βStem6 Skin Longevity Data Presented at S.E.A.S.O.N International Summit

EntSun News/11093494
WASHINGTON - EntSun -- Genesis Molecular Technologies, Inc. (GMT), a longevity science company focused on advancing regenerative technologies for healthy aging, announced that Dr. Gail K. Naughton, PhD, MBA, member of the GMT Board of Directors and internationally-recognized biotechnology pioneer, will present new ex-vivo human skin data on GMT's proprietary molecule βSTEM6 at the prestigious S.E.A.S.O.N. International Summit on
Aesthetic Medicine this weekend in Washington, D.C.

The presentation highlights the latest findings from a controlled ex-vivo human skin study designed to evaluate the ability of βSTEM6 to address multiple hallmarks of skin aging through comprehensive immunohistochemical analysis and gene-expression profiling. The study compared βSTEM6 against established industry standards, including retinol and retinoic acid.

Results demonstrated a distinctly different biological profile for βSTEM6. While retinol and retinoic acid produced broad increases in proliferation, stress-response, and turnover-associated genes, βSTEM6 exhibited a highly selective, time-dependent modulation of pathways associated with basal keratinocyte function, cellular adhesion, and senescence. Importantly, these effects were achieved without disrupting normal skin differentiation or epidermal barrier integrity - key indicators of maintaining healthy skin architecture and function.

More on EntSun News
"These findings further strengthen the growing body of evidence supporting βSTEM6 as a novel skin longevity technology," said Paul Scott Premo, Chief Executive Officer of Genesis Molecular Technologies. "The data corroborate previous clinical observations and molecular analyses, demonstrating the unique ability of βSTEM6 to support endogenous stem cell activity, promote skin rejuvenation, and help reverse biological markers associated with skin aging. We believe this technology has the potential to redefine the future of regenerative skincare and longevity-focused dermatology."

βSTEM6 is a patented, synthetic small molecule and highly selective antagonist of the CBP/β-catenin interaction, a critical regulatory pathway involved in stem cell biology, tissue regeneration, and aging. By modulating this pathway with exceptional biochemical specificity, βSTEM6 is designed to promote healthy cellular renewal while maintaining normal tissue homeostasis.

About Genesis Molecular Technologies
GENESIS MOLECULAR TECHNOLOGIES, INC. is a longevity science company focused on the discovery and development of next-generation technologies designed to enhance health span, tissue regeneration, and healthy aging. The company's innovation platform is built around its proprietary, patented CBP/β-catenin antagonist technology, βSTEM6.

More on EntSun News
βSTEM6 is a novel, patented Skin Longevity Molecule™ engineered to support the body's natural regenerative processes through the selective modulation of Wnt/β-catenin signaling. By promoting asymmetric stem cell division and cellular renewal pathways, βSTEM6 has demonstrated the ability to enhance skin regeneration, support extracellular matrix remodeling, inhibit collagen degradation, stimulate collagen and glycosaminoglycan (GAG) synthesis, and improve overall skin health and appearance. Through its unique mechanism of action, βSTEM6 represents a new approach to addressing the biological markers of skin aging and longevity.

Contact
Gail K. Naughton
***@regenemedassoc.com


Source: Genesis Molecular Technologies, Inc.
Filed Under: Beauty

Show All News | Disclaimer | Report Violation

0 Comments

Latest on EntSun News